Harrow Surges with IHEEZO and VEVYE Momentum | Business and Finance News

Harrow’s second quarter is exploding with momentum, fueled by record demand for IHEEZO and VEVYE, both now operating at razor-thin margins and soaring prescription volumes. Despite losing pass-through status, IHEEZO’s price hike pushed gross margins over 90%, while VEVYE’s prescriptions jumped 21% sequentially thanks to new rules and a doubled sales force. Their specialty portfolio is also on fire: TRIESENCE hit another demand peak with half its sales from ocular surgery, Byooviz launched strong, VERKAZIA relaunched, and IOPIDINE now has permanent J-code access — all supported by expanded commercial teams. Revenue surged 11% YoY to $70.7M, with the second half poised to outperform after first-half headwinds. Looking ahead, Harrow’s blockbuster move to acquire global rights to TYRVAYA — a dry eye treatment with no contraindications — could be their biggest deal ever, strategically expanding their dry eye franchise. They’re targeting stronger demand, better economics, wider access, and amplified commercial support across key drivers, with an Investor Day set for March 22, 2027, in NYC. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/41b33d7c65800481